Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients:A Retrospective Study of 855 Cases

Xian-ge HUANG; Li-hua ZHU; Lei ZHOU; Wei-jie XU; Yi-lin YAO; Zhi-yi ZHOU; He-gen LI

doi:10.1007/s11655-020-3428-5

Your Location：

Home >

Browse articles >

Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients:A Retrospective Study of 855 Cases

Original Article | Updated：2021-09-01

- Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients:A Retrospective Study of 855 Cases
- Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients:A Retrospective Study of 855 Cases
- Chinese Journal of Integrative Medicine 2021年27卷第7期页码：490-495
- Affiliations：
  
  The Third Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai (200032), China
- Author bio：
  
  Prof. LI He-gen, E-mail: shlaogen@163.com
- Funds：
  
  National Thirteenth Five-Year Science and Technology Major Special Project for New Drug Innovation and Development(2017ZX09304001);Shanghai Three-Year Action Plan for Further Accelerating the Development of TCM(ZY (2018-2020)-CCCX-1016);Shanghai TCM Medical Center of Chronic Disease(2017ZZ01010);Pudong New Area Health Select Committee Health and Family Planning Scientific Research Project Plan(PW2019E-1);Shanghai Key Clinical Specialty Project(shslczdzk03701)
- DOI：10.1007/s11655-020-3428-5
  中图分类号：
- 纸质出版日期：2021-07-01，
  
  网络出版日期：2020-09-02，
  
  录用日期：2020-06-22
Scan for full text
Xian-ge HUANG, Li-hua ZHU, Lei ZHOU, 等. Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients:A Retrospective Study of 855 Cases[J]. Chinese Journal of Integrative Medicine, 2021,27(7):490-495.

Xian-ge HUANG, Li-hua ZHU, Lei ZHOU, et al. Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients:A Retrospective Study of 855 Cases[J]. Chinese Journal of Integrative Medicine, 2021,27(7):490-495.
Xian-ge HUANG, Li-hua ZHU, Lei ZHOU, 等. Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients:A Retrospective Study of 855 Cases[J]. Chinese Journal of Integrative Medicine, 2021,27(7):490-495. DOI： 10.1007/s11655-020-3428-5.

Xian-ge HUANG, Li-hua ZHU, Lei ZHOU, et al. Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients:A Retrospective Study of 855 Cases[J]. Chinese Journal of Integrative Medicine, 2021,27(7):490-495. DOI： 10.1007/s11655-020-3428-5.

摘要

Abstract

Objective:

To investigate the effects of multidisciplinary and comprehensive Chinese medicine (CM) treatments on progression-free survival (PFS) and median survival time (MST) in patients with advanced nonsmall cell lung cancer (NSCLC) and identify factors that influence progression and prognosis.

Methods:

Clinical data of 855 patients with advanced NSCLC who received multidisciplinary and comprehensive CM treatments at Longhua Hospital from January 2009 to December 2018 were retrospectively analyzed. Univariate analysis was performed by the Kaplan-Meier method and log-rank sequential inspection. Multivariate analysis of significant variables from the univariate analysis was performed with Cox regression modeling. Key factors correlated to progression and prognosis were screened out

and a Cox proportional hazard model was established to calculate the prognostic index.

Results:

The PFS and MST of 855 advanced NSCLC patients were 9.0 and 26.0 months

respectively. The 1-

and 5-year survival rates were 79.2%

54%

36.2%

and 17.1%

respectively. Gender

pathologic type

and clinical stage were independent prognostic risk factors; surgical history

radiotherapy

treatment course of Chinese patent medicine

intravenous drip of Chinese herbal preparation

duration of oral administration of Chinese herbal decoction (CHD)

and intervention measures were independent prognostic protective factors. Gender was an independent risk factor for progression

while operation history and oral CHD administration duration were independent protective factors (all

0.05). Women with stage Ⅲb–Ⅲc lung adenocarcinoma had the best outcomes.

Conclusions:

Female patients have lower progression risk and better prognoses than male patients

younger patients have higher progression risk but better long-term prognoses than the elderlys

and patients with lower performance status scores are at lower risk for progression and have better prognoses. Comprehensive CM treatments could significantly reduce progression risk

improve prognosis

and prolong survival time for patients with advanced NSCLC. This treatment mode offers additional advantages over supportive care alone.

关键词

Keywords

advanced non-small cell lung cancerprognostic factorprogression factorsurvival analysisChinese medicine

references

RS Zheng, KX Sun, SW Zhang, HM Zeng, XN Zou, R Chen, et al. Report of cancer epidemiology in China, 2015. Chin J Oncol (Chin) 2019;41:19-28.

RL Siegel, KD Miller, A Jemal. Cancer statistics, 2019. CA-Cancer J Clin 2019;69:7-34.

WQ Chen, RS Zheng, PD Baade, S Zhang, H Zeng, F Bray, et al. Caner statistics in China, 2015. CA Cancer J Clin 2016;66:115-132.

Chinese Anticancer Association.New criteria of diagnosis and treatment for common malignant tumors. Beijing: Beijing Union Medical University Press;1999:773-781.

P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, WEE Eberhardt. The IASLC Lung Cancer Staging Project:proposals for revision of the TNM Stage Groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016;11:39-51.

XY Zheng, ed. Guidelines of traditional Chinese medicine new drugs for the clinical research. Beijing: China Medical Science and Technology Press; 2002:217-218.

Shanghai Municipal Health Bureau.Shanghai routine of diagnosis and treatment of TCM disease and syndrome.Shanghai: Shanghai University of Tradition Chinese Medicine Press; 2003:128.

JL Sun, CJ Li, HG Li, LS Liu, JH Tian. An introduction of LIU Jia-xiang's academic thought about 'strengthening vital qi to treat cancer'. J Tradit Chin Med (Chin) 2006;47:814-816.

CC Zhou. A revision of NCCN guideline for non-small cell lung cancer 2008. Tumor (Chin) 2008;28:183-186.

LA Torre, F Bray, RL Siegel, J Ferlay, J Lortet-Tieulent, A Jemal.Global cancer statistics, 2012. CA Cancer J Clin 2015;65:69-90.

U Ahmad, M Ruschel, FC Detterbeck. Lung cancer:facts, figures and reflections on spending. J Cancer Ther 2012;3:123-126.

HG Li. Professor LIU Jia-xiang's treatment experience of lung cancer is based on scientific theory system about'strengthening vital qi to treat cancer'. J Sichuan Tradit Chin Med (Chin) 2005;7:5-6.

JH Tian, B Luo, JX Liu. Biological basis of hidden toxicity due to vital qi deficiency in lung cancer: Ⅰ. Discussion on vital qi deficiency in lung cancer from immunologic derangement.Shanghai J Tradit Chin Med (Chin) 2018;52:1-4.

JH Tian, B Luo. Biological basis of hidden toxicity due to vital qi deficiency in lung cancer: Ⅱ. Discussion on hidden toxicity in lung cancer from occult tumor cells. Shanghai J Tradit Chin Med (Chin) 2018;52:6-10.

JL Yao, YB Gong, L Xu. Role of Chinese medicine therapy in postoperative rehabilitation of lung cancer survivors. Med Recapit (Chin) 2017;23:4721-4725.

XW Guo, ND Hu, GZ Sun, M Li, PT Zhang. Shenyi Capsule plus chemotherapy versus chemotherapy for non-small cell lung cancer: a systematic review of overlapping meta-analyses. Chin J Integr Med 2018;24:227-231.

YZ Chen, ZD Li, N Zhou, H Sun, PP Li. Longer overall survival in a patient with advanced NSCLC treated with Chinese medicine and chemotherapy. Chin J Integr Med 2012;18:626-628.

XB Yang, XS Chai, WY Wu, SQ Long, H Deng, ZQ Pan, et al. Gefitinib plus Fuzheng Kang'ai Formula in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: a randomized controlled trial. Chin J Integr Med 2018;24:734-740.

XR He, SY Han, PP Li. Recent highlights of Chinese medicine for advanced lung cancer. Chin J Integr Med 2017;23:323-330.

WJ Xu, HG Li, YQ Pu, LH Zhao, JH Tian, LH Zhu, et al.Retrospectively study of traditional Chinese medicine in the treatment of advanced non-small cell lung cancer. Acad J Shanghai Univ Tradit Chin Med (Chin) 2017;3105:27-31.

YZ Chen, XB Feng, ZD Li, WX Zheng, H Sun, PP Li. Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and Western medicine. Chin J Integr Med 2014;20:179-183.

HZ Xu, X Zhang, JL Sun. Multi-factor analysis of EGFR-TKIs combined with TCM in the treatment of NSCLC. Li Shi-zhen Med Mater Med Res (Chin) 2017;28:2156-2158.

XL Xin, Yi Jiang, LP Shen, LS Liu. Survival analysis of 600 elderly patients with non-small cell lung cancer treated with traditional Chinese medicine. J Tradit Chin Med (Chin)2019;60:31-35.

AM Gregory, T Sarah, GA Christopher, G Giuseppe, B Sherman, RB Julie, et al. Systemic therapy for stage Ⅳ non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2015;33:3488-515.

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models

Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

Immunoregulatory and Anti-cancer Activities of Combination Treatment of Novel Four-Herb Formula and Doxorubicin in 4T1-Breast Cancer Bearing Mice

TRAIL and Celastrol Combinational Treatment Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells via Targeting Wnt/β-Catenin Signaling Pathway